Herpes simplex virus

Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

Retrieved on: 
Wednesday, November 8, 2023
University of Washington Department of Global Health, Stanford University, Bio, Infection, Therapy, Viral, Biotechnology, Herpes simplex virus, BS, MD, Publication, Doctor of Philosophy, Gilead Sciences, Sofosbuvir, University, Assembly, HCV, Virology, Chemistry, Patient, HDV, HBV, SAN, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer. Dr. Gaggar is an infectious disease specialist and seasoned executive whose experience has focused on the development of new therapies in viral diseases including chronic hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis D virus (HDV) infections.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer.
  • “We are excited to have Dr. Gaggar join Assembly Bio’s leadership team at an incredibly important time for the organization,” said Jason Okazaki, chief executive officer and president.
  • Dr. Gaggar was a clinical fellow in infectious diseases at the University of California, San Francisco, where he also served as chief resident.
  • He received his MD and PhD from the University of Washington and his BS in chemistry from Stanford University.

Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC

Retrieved on: 
Saturday, November 4, 2023
Research, Arm, Society for Immunotherapy of Cancer, Intelligence, HSV, Therapy, Enlightenment, ICI, Herpes simplex virus, CADL, MD, Doctor of Philosophy, Nature, SITC, Immunotherapy, Neoplasm, Biology, Drug discovery, Machine learning, Annual general meeting, Tumor microenvironment, Bone marrow, Patient, Toxicity, Content discovery platform, Vaccine, Pharmaceutical industry, Candel, Fellow of the Academy of Medical Sciences

“We aim to leverage artificial intelligence and machine learning to expedite various aspects of drug discovery and development,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel.

Key Points: 
  • “We aim to leverage artificial intelligence and machine learning to expedite various aspects of drug discovery and development,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel.
  • “Tumor resistance to immunotherapy is driven by multiple mechanisms, which are heterogeneous in nature,” said Francesca Barone, MD, PhD, Chief Scientific Officer at Candel.
  • “The Alpha-201-macro1 preclinical data presented today support the utility of local delivery of an immunologically active, multimodal agent as a potential alternative to systemic therapy.
  • We are excited to leverage the enLIGHTEN™ Discovery Platform to optimize the immunostimulatory payload of this agent for activation of innate immune surveillance with the goal of maximizing its therapeutic potential.”
    Further details from the posters are available on the Candel website at: www.candeltx.com/media

Excision BioTherapeutics Announces Gene Therapy Publication of Pre-Clinical Data Supporting its First-in-Class CRISPR-Based Gene Therapy Candidate Designed to Functionally Cure HIV-1

Retrieved on: 
Thursday, August 17, 2023
Tissue, HIV/AIDS, DNA, CRISPR, Herpes simplex virus, Therapy, Gene, Senior, HIV, Temple University, SIV, Gene editing, Clinical trial, ART, Toxicity, Infection, Doctor of Philosophy, Science, Northwest Biotherapeutics, Animal, Risk, Primate, SAN, Blood, Safety, Autopsy, Pharmaceutical industry, Vaccine, Excision, Research, Medicine

The data support the safety, biodistribution, and on-target editing of Excision’s EBT-101 program targeting HIV, which is being evaluated in first-in-human Phase 1/2 clinical trials.

Key Points: 
  • The data support the safety, biodistribution, and on-target editing of Excision’s EBT-101 program targeting HIV, which is being evaluated in first-in-human Phase 1/2 clinical trials.
  • “We are very excited by the positive data generated in this study, which set the foundation for an important first-in-human clinical trial of our lead candidate, EBT-101,” said Daniel Dornbusch, Chief Executive Officer of Excision.
  • The newly published data supplement the efficacy data generated in previous pre-clinical studies of EBT-101, demonstrating excision of integrated proviral SIV DNA in vivo, without any detectable off-target effects.
  • “These newly published results demonstrate the tremendous potential of EBT-101 to shape the future of HIV therapeutics,” said Dr. Khalili.

Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 30, 2023
HSV, Pancreatic cancer, Insurance, Herpes simplex virus, University, Partnership, ICI, Survival, Clinical trial, Silicon Valley Bank, Immunotherapy, Nestin, Toxicity, Brain, NSCLC, Lung cancer, Doctor of Philosophy, TWELVE, Rated R, MS, University of Pennsylvania, Silicon, Development, HIV disease progression rates, Patient, Standard of care, Content discovery platform, Administration, HGG, Biology, PD-1, Research, Therapy, CADL, Tumor microenvironment, PD-L1, Valaciclovir, Nivolumab, Prostate cancer, Enlightenment, Pharmaceutical industry, Vaccine, Medical imaging, Cryptocurrency, Society, Candel, SOC, Cancer, Fellow of the Academy of Medical Sciences, MD

In addition, a single injection of CAN-3110 in patients with recurrent high-grade glioma resulted in a median overall survival of 11.6 months.

Key Points: 
  • In addition, a single injection of CAN-3110 in patients with recurrent high-grade glioma resulted in a median overall survival of 11.6 months.
  • Importantly, CAN-2409 demonstrated a favorable change in the trajectory of tumor growth in all patients for whom pre-enrollment scans were available.
  • The Company is encouraged by the results and plans to present additional data in Q3 2023.
  • Research and Development Expenses: Research and development expenses were $5.0 million for the fourth quarter of 2022 compared to $3.9 million for the fourth quarter of 2021, and $20.8 million for the full-year 2022 compared to $15.2 million for the full-year 2021.

BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163

Retrieved on: 
Wednesday, December 21, 2022
Ageing, Invention, RNA transfection, University of Pennsylvania, Research, Distress, HIV, Glycoprotein, Global health, Risk, BNTX, Infection, Meningitis, Herpes simplex virus, World Health Organization, HSV epigenetics, Safety, Penn, University, BioNTech, IND, Immunity, HSV, History, HSV-2, Pharmaceutical industry, Vaccine

The trial ( NCT05432583 ) will evaluate the safety, tolerability, and immunogenicity of BNT163.

Key Points: 
  • The trial ( NCT05432583 ) will evaluate the safety, tolerability, and immunogenicity of BNT163.
  • Editor’s Note: The University of Pennsylvania has licensed some intellectual property related to the BNT163 vaccine candidate to BioNTech.
  • The University of Pennsylvania receives sponsored research funding from BioNTech related to preclinical development of the BNT163 vaccine candidate.
  • As inventors of certain intellectual property related to the BNT163 vaccine candidate, some of the scientists involved in the preclinical development of the candidate along with Penn, may receive additional financial benefits under the BioNTech license in the future.

Outstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidate

Retrieved on: 
Tuesday, December 20, 2022
Spleen, Vaccination, Herpes simplex virus, Vaccine, Ganglion, Infection, CD8, RNA transfection, HSV-2, Mouse, News, Immunization, CD4, Relevant

The initial results demonstrate that immune responses in mice immunized with the mRNA candidate are not only non-inferior to those elicited by their protein counterpart.

Key Points: 
  • The initial results demonstrate that immune responses in mice immunized with the mRNA candidate are not only non-inferior to those elicited by their protein counterpart.
  • In fact, the mRNA vaccine generates superior T cell responses.
  • Results from the study, comparing the two technology platforms at multiple doses, demonstrate that the mRNA and the protein vaccines were well tolerated and generated T cell and antibody responses.
  • "I am overwhelmed by these results" says Dr. Karl Ljungberg, Director of Preclinical Development at Eurocine Vaccines.

Outstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidate

Retrieved on: 
Tuesday, December 20, 2022
Spleen, Vaccination, Herpes simplex virus, Vaccine, Ganglion, Infection, CD8, RNA transfection, HSV-2, Mouse, News, Immunization, CD4, Relevant

The initial results demonstrate that immune responses in mice immunized with the mRNA candidate are not only non-inferior to those elicited by their protein counterpart.

Key Points: 
  • The initial results demonstrate that immune responses in mice immunized with the mRNA candidate are not only non-inferior to those elicited by their protein counterpart.
  • In fact, the mRNA vaccine generates superior T cell responses.
  • Results from the study, comparing the two technology platforms at multiple doses, demonstrate that the mRNA and the protein vaccines were well tolerated and generated T cell and antibody responses.
  • "I am overwhelmed by these results" says Dr. Karl Ljungberg, Director of Preclinical Development at Eurocine Vaccines.

City of Hope scientists develop new potential treatment for brain tumors

Retrieved on: 
Tuesday, November 29, 2022
Herpes simplex virus, Haematopoietic system, Translational Genomics Research Institute, Glioblastoma, Macrophage, Organization, Brain, Food, Cell, National Cancer Institute, City, Multimedia, Patient, City of Hope, Neoplasm, Tumor microenvironment, City of Hope National Medical Center, EGFR, Research, CAR, Disease, Diabetes, NK, Cancer Treatment Centers of America, GBM, CCL5, Criticism of the Food and Drug Administration, Biology, Mouse, Deana, Cetuximab, National Cancer Center, Chemokine, Survival, Immunotherapy, Caligiuri, Vaccine, Medical imaging, Hope

LOS ANGELES, Nov. 29, 2022 /PRNewswire/ -- Glioblastoma multiforme (GBM), the most common type of brain cancer, is notoriously difficult to treat. Its tumor cells mutate rapidly, pushing into deep areas of the brain that can be difficult to reach with surgery and other treatments. GBMs are also able to turn off the mechanism that typically brings immune cells to a damaged area of the body, so that immunotherapies don't work against the disease.

Key Points: 
  • Scientists with City of Hope, one of the largest cancer research and treatment organizations in the United States, have developed a new approach to attract immune cells to brain tumors.
  • To overcome those challenges, scientists with City of Hope, one of the largest cancer research and treatment organizations in the United States, have developed a new approach to attract immune cells to these tumors.
  • The immune cells have to cross through the blood brain barrier to get to the brain.
  • For more information about City of Hope, follow us on Facebook , Twitter , YouTube , Instagram and LinkedIn .

Candel Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for CAN-2409 in Glioma

Retrieved on: 
Thursday, September 15, 2022
Herpes simplex virus, CADL, FDA, MD, COMP, Brain, Food, Virus, European Medicines Agency, European Commission, Company, Population, Pancreatic cancer, Private Securities Litigation Reform Act, Therapy, Valaciclovir, Person, Neoplasm, Patient, Clinical trial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, Disease, CEO, Technology, Nasdaq, Doctor of Philosophy, Immunogenic cell death, HSV, Lung, Tumor microenvironment, Committee, Large-cell lung carcinoma, Prostate cancer, Royal commission, SEC, Union, Mortality, Content discovery platform, Marketing, GLOBE, EMA, Pharmaceutical industry, Vaccine, Fellow of the Academy of Medical Sciences, EU, Candel, Glioma

The orphan drug designation follows the U.S. Food and Drug Administration (FDA) fast track designation, which was granted in June 2021, for CAN-2409 in combination with valacyclovir following standard of care treatment in newly diagnosed high-grade glioma.

Key Points: 
  • The orphan drug designation follows the U.S. Food and Drug Administration (FDA) fast track designation, which was granted in June 2021, for CAN-2409 in combination with valacyclovir following standard of care treatment in newly diagnosed high-grade glioma.
  • Paul Peter Tak, MD, PhD, FMedSci, President and CEO of Candel, said, "Glioma, while mercifully rare, is a devastating disease with significant morbidity and mortality.
  • The EMA's orphan drug designation recognizes the high unmet need and the potential of CAN-2409 in this patient population.
  • Orphan drug designation in the European Union (EU) is granted by the European Commission based on a positive opinion issued by the EMA COMP.

Global Gene Therapy Market Analysis Report 2022: M&As Rampant in the Gene Therapy Space - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 18, 2022
Health, Genetics, CAR, Vaccinia, Growth, Investment, Cancer, Incidence, Prevalence, Research, Government, Gene, DNA, COVID-19, Lists of diseases, Conditional sentence, Biotechnology, RNA, Safety, Awareness, CAGR, Virus, Herpes simplex virus, Retrovirus, AAV, Fine chemical, Pharmaceutical industry, Vaccine, Pet, Lentivirus, Poxviridae

The "Gene Therapy - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gene Therapy - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Gene Therapy estimated at US$1.2 Billion in the year 2022, is projected to reach a revised size of US$2.7 Billion by 2026, growing at a CAGR of 19.5% over the analysis period.
  • Non-viral vectors are perceived as safer substitute to viral vectors, and playing an important role in redirecting pharmaceutical industries and clinicians towards gene therapy.
  • In Europe, rising funding for cell and gene therapy programs in countries such as the UK is expected to steer the gene therapy market in the region.